Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02045693 | Drug Interaction & Methadone & Buprenorphine | PHASE1 | COMPLETED | 32 | — | — | Feb 1, 2014 | Apr 1, 2014 | Jun 17, 2014 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Part 1: Methadone + DCV 3DAA FDC + BMS-791325 | EXPERIMENTAL | Methadone 40-120 mg tablet or solution orally once on Day 1 Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
| Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325 | ACTIVE_COMPARATOR | Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1 Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12 |
| Name | Type | Description |
|---|---|---|
| Methadone | DRUG | - |
| DCV 3DAA FDC | DRUG | - |
| BMS-791325 | DRUG | - |
| Buprenorphine | DRUG | - |
| Naloxone | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Subject must be on stable Methadone or Buprenorphine regimens for at least 28 days prior to screening Exclusion Criteria: * Subjects must be healthy except for history of M...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |